Antabio, a French biopharmaceutical company, has received a €4.7 Million Wellcome Trust Seeding Drug Discovery Award to develop novel small molecule drugs for the treatment of life-threatening infections caused by multi-drug resistant Gram-negative bacteria. Multi-drug resistant Gram-negative bacteria account for most hospital infections worldwide, causing up to 75,000 deaths yearly and extra healthcare costs/productivity losses of >€ 1.5 billion.
Harlow, UK and Labège, France – Argenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has signed a collaboration agreement with Antabio. Under the terms of the agreement, Argenta will provide medicinal chemistry, computer-aided drug design and ADME/PK services.
Antabio and WiSEED announce the first successful round of crowdfunding applied to biotech start-up financing
Antabio, the biopharmaceutical antibacterial drug discovery company, and WiSEED, the French crowdfunding platform dedicated to innovative & technologic startups, announce the successful completion of their seed round of financing with a profitable exit of the initial small investors, a world premiere in the field of crowdfunding applied to biotech start-up financing.
Antabio, the biopharmaceutical antibacterial drug discovery company, welcomes M. Christophe RICARD former CEO of the Swiss pharmaceutical group OM Pharma as its new investor. Under Mr RICARD’s leadership, OM Pharma developed and commercialized two record selling drugs aimed at preventing and treating bacterial infections, Broncho-Vaxom® and Uro-Vaxom®, prior to being acquired by the Galenica group in 2009.
Antabio, a biopharmaceutical expert in the fight against nosocomial bacterial infections, announces the raising of 309 K€ as a first part of its 1 million euro seed financing round. The young french start-up addresses a growing global health problem, recognized as n°1 priority by the World Health Organization. Antabio develops the next generation of antibacterial drugs that treat major hospital infections by blocking the virulence of pathogenic bacteria.
BioMedicalAlliance is a not for profit organization supporting the biopharma industry in the Midi-Pyrenees region (France).
The Club Galaxie Award rewards the best ideas supporting the incorporation of an innovative company in the Midi-Pyrenees region. The Club Galaxie, founded in 2001, is composed of more than 78 executive leaders of small businesses, large corporations, industry and services as well as higher education and research entities in the Toulouse area, from over 20 different professional sectors.